Cellectis S.A.
CLLS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001627281
No open-market purchases or sales by Cellectis S.A. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $28.4M in total; no superinvestor holds it.
Q2 2025 vs. Q1 2025
How the institutions holding Cellectis S.A. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Q2 2025 | Change |
|---|---|---|---|
| Holders | 27 | 24 | −3 |
| Shares | 13.6M | 11.8M | −1.84M (−13.6%) |
| Value | $16.9M | $17.9M | +$989.6K (+5.9%) |
New holders (3)
Institutions that held Cellectis S.A. at the end of Q2 2025 but not at the end of Q1 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Susquehanna International Group, LLP | 34,433 | $52.0K | 0.00% |
| Raymond James Financial Inc | 1,132 | $1.73K | 0.00% |
| Advisor Group Holdings, Inc. | 100 | $152 | 0.00% |
Sold out (6)
Institutions that held Cellectis S.A. at the end of Q1 2025 and filed for Q2 2025 without it.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| Baillie Gifford & Co | 139,047 | $172.4K |
| Old Mission Capital LLC | 25,289 | $31.4K |
| Baird Financial Group, Inc. | 15,090 | $18.7K |
| Cubist Systematic Strategies, LLC | 10,859 | $13.5K |
| Geode Capital Management, LLC | 10,776 | $13.4K |
| Federation des caisses Desjardins du Quebec | 10,711 | $13.3K |